Study Summary
This trial tests whether a new anticoagulant drug is better than placebo to reduce ischemic stroke risk for people who recently had a non-cardioembolic stroke or temporary stroke-like symptoms. It also checks for major bleeding risks and quality of life.
- Stroke Prevention
- Ischemic Stroke
- Transient Ischemic Attack (TIA)
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 15 Secondary · Reporting Duration: Up to 31 months
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Asundexian
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group
9300 Total Participants · 2 Treatment Groups
Primary Treatment: Asundexian · Has Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Has Asundexian received regulatory clearance from the FDA?
"Our team at Power assessed Asundexian's safety to be a 3 out of 3 due to data from clinical trials suggesting efficacy as well as several rounds of information validating the drug's security." - Anonymous Online Contributor
How many administrative centers are responsible for the management of this research?
"HonorHealth in Scottsdale, Banner - University Medical Center Tucson in Tucson, and MemorialCare Health System in Long Beach are some of the sites performing this trial. Additionally, there are 65 other medical facilities participating across America." - Anonymous Online Contributor
Are there currently any available positions for volunteers to participate in this trial?
"Data on clinicaltrials.gov shows that this particular medical investigation is not presently recruiting patients, despite having initially posted the trial on February 16th 2023 and most recently updating it on January 6th 2023. However, there are 1285 other studies actively seeking participants at this time." - Anonymous Online Contributor